Aadi Bioscience, Inc. (NASDAQ:AADI) CEO David James Lennon Sells 5,690 Shares

Aadi Bioscience, Inc. (NASDAQ:AADI) CEO David James Lennon sold 5,690 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $2.35, for a total value of $13,371.50. Following the completion of the sale, the chief executive officer now owns 33,429 shares of the company’s stock, valued at approximately $78,558.15. This represents a 14.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Aadi Bioscience Trading Down 10.2 %

Shares of NASDAQ AADI opened at $2.30 on Tuesday. Aadi Bioscience, Inc. has a 12-month low of $1.21 and a 12-month high of $3.81. The company has a market cap of $56.80 million, a P/E ratio of -1.01 and a beta of 0.64. The stock has a fifty day moving average price of $2.95 and a 200 day moving average price of $2.37.

Institutional Trading of Aadi Bioscience

Several large investors have recently added to or reduced their stakes in AADI. QVT Financial LP acquired a new stake in Aadi Bioscience in the 4th quarter valued at $7,300,000. BML Capital Management LLC acquired a new stake in shares of Aadi Bioscience during the third quarter valued at about $4,120,000. Acorn Capital Advisors LLC acquired a new stake in shares of Aadi Bioscience during the fourth quarter valued at about $3,619,000. Ally Bridge Group NY LLC acquired a new stake in shares of Aadi Bioscience during the fourth quarter valued at about $2,581,000. Finally, Peapod Lane Capital LLC acquired a new stake in shares of Aadi Bioscience during the fourth quarter valued at about $1,397,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.